Akebia Therapeutics
AKBA
155 hedge funds and large institutions have $703M invested in Akebia Therapeutics in 2020 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 53 increasing their positions, 43 reducing their positions, and 22 closing their positions.
676% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $1.4M
32% more capital invested
Capital invested by funds: $532M → $703M (+$171M)
23% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 43
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
1% more funds holding
Funds holding: 153 → 155 (+2)
0.61% more ownership
Funds ownership: 70.83% → 71.43% (+0.61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$55.4M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.72M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$8.83M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.7M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$15.9M |
| 2 |
Morgan Stanley
New York
|
-$6.29M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5.36M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$5.03M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.99M |
AKBA Hedge Fund Activity: Q1 2020 in Review
155 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2020, worth a combined $703M — up 32% from $532M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new AKBA positions and 22 closed out — a net gain of 5 holders — while 53 added to existing stakes and 43 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $55.4M. The largest seller was Baupost Group, cutting an estimated $15.9M.
- 155 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2020, up from 153 in Q4 2019.
- Funds reported $703M of Akebia Therapeutics stock for Q1 2020, up 32% quarter-over-quarter.
- 27 funds opened new Akebia Therapeutics positions in Q1 2020 and 22 closed out, a net change of +5 holders.
- The largest Akebia Therapeutics buyer in Q1 2020 was Consonance Capital Management, an estimated $55.4M added.
- The largest Akebia Therapeutics seller in Q1 2020 was Baupost Group, an estimated $15.9M sold.
Based on aggregated 13F filings for Q1 2020.